CTIC...$2.74...in the P/M...Setting up open gap this A.M.following the $1.05 close...
CTI BioPharma to Submit a New Drug Application (NDA) for the Accelerated Approval of Pacritinib for the Treatment of Myelofibrosis Patients with Severe Thrombocytopenia - Company to Proceed with Rolling NDA Submission following Recent Pre-NDA Meeting with FDA - - Rolling NDA Expected to Commence in the Fourth Quarter of 2020 - - Completion of NDA Submission Expected in First Quarter 2021 - - Company to Host Conference Call on Wednesday, September 30 at 8:30 AM ET
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.